{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:19Z","timestamp":1789578319659,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTRQQR-2021\\\\100009"],"award-info":[{"award-number":["CTRQQR-2021\\\\100009"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["CEO13_2-002"],"award-info":[{"award-number":["CEO13_2-002"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["20YOUN17"],"award-info":[{"award-number":["20YOUN17"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["18CHAL06"],"award-info":[{"award-number":["18CHAL06"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020400","name":"John Black Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.02.014","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:45:13Z","timestamp":1773261913000},"page":"804-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel ROR\u03b3\/ROR\u03b3t Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Rafael","family":"Grochot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bertan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rekowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Abramowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Riisnaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Gurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Los Dolores","family":"Fenor de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khobe","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Westaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hella","family":"Kohlhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Paschalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.02.014_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.02.014_b0010","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.euo.2026.02.014_b0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL23 secreted by myeloid cells drives castration resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.euo.2026.02.014_b0020","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.4070","article-title":"ROR-\u03b3 drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer","volume":"22","author":"Wang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.02.014_b0025","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.euo.2026.02.014_b0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cpdd.1243","article-title":"Safety, tolerability, and pharmacokinetics of imu-935, a novel inverse agonist of retinoic acid receptor\u2013related orphan nuclear receptor \u03b3t: results from a double-blind, placebo-controlled, first-in-human phase 1 study","volume":"12","author":"Polasek","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.euo.2026.02.014_b0035","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.014_b0040","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2026.02.014_b0045","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/ATVBAHA.115.307080","article-title":"Inhibition of the nuclear receptor ROR\u03b3 and interleukin-17A suppresses neovascular retinopathy","volume":"36","author":"Talia","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.euo.2026.02.014_b0050","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/art.30582","article-title":"Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement","volume":"63","author":"Moran","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.euo.2026.02.014_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.06.003","article-title":"Glia\u2013neuron interactions in the mammalian retina","volume":"51","author":"Vecino","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.euo.2026.02.014_b0060","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41388-024-03005-4","article-title":"DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer","volume":"43","author":"Guo","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.euo.2026.02.014_b0065","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.euo.2026.02.014_b0070","first-page":"S37","article-title":"Mismatch repair deficiency and clinical implications in prostate cancer","volume":"82","author":"Graham","year":"2022","journal-title":"Prostate"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:47:45Z","timestamp":1789577265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126000519"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.014","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel ROR\u03b3\/ROR\u03b3t Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}